Mirum Pharmaceuticals Inc

Despite long-term upward momentum from the rising 200-day SMA, MIRM is consolidating under the 9/20/50 EMAs without clear pattern. This distribution-phase context yields a medium-term bearish bias, favoring defensive sell-side execution on rallies into the 20/50 EMA zone. Short-term timing remains neutral, calling for patience and trimming exposure at resistance rather than immediate exits.

• ↑Q2 net product sales increased 37.5% YoY to $176M, reflecting strong execution.
• ↑Full-year 2026 sales guidance upped to $680–$700M, underscoring management confidence.
• ↓Negative earnings yield and weak profitability metrics suggest cash-flow risks.